Portal de Periódicos da CAPES

Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and Futuna

2022; Elsevier BV; Volume: 30; Linguagem: Inglês

10.1016/j.lanwpc.2022.100634

2666-6065

Antoine Brault, Cécile Tran Kiem, Clément Couteaux, Valérie Olié, Juliette Paireau, Yazdan Yazdanpanah, Jade Ghosn, Guillaume Martin‐Blondel, Paolo Bosetti, Simon Cauchemez,

Influenza Virus Research Studies

Ending Zero-COVID is challenging, particularly when vaccine coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by reluctance to vaccination, low immunity and high levels of comorbidities, we investigate how targeted use of nirmatrelvir/ritonavir (brand name Paxlovid) can complement vaccination and non-pharmaceutical interventions (NPIs), and mitigate the epidemic rebound expected when Zero-COVID ends.